Beclabuvir(BMS-791325)|Supplied by DC Chemicals

Cas No.:	958002-33-0
Chemical Name:	(4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo[3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
Synonyms:	BMS-791325
SMILES:	O=C(N1C2CCC1CN(C)C2)[C@@]3(CN4C5=C(C6CCCCC6)C7=CC=C(C(NS(N(C)C)(=O)=O)=O)C=C47)[C@H](C8=CC(OC)=CC=C85)C3
Formula:	C₃₆H₄₅N₅O₅S
M.Wt:	659.31
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

For the detailed information of Beclabuvir(BMS-791325), the solubility of Beclabuvir(BMS-791325) in water, the solubility of Beclabuvir(BMS-791325) in DMSO, the solubility of Beclabuvir(BMS-791325) in PBS buffer, the animal experiment (test) of Beclabuvir(BMS-791325), the cell expriment (test) of Beclabuvir(BMS-791325), the in vivo, in vitro and clinical trial test of Beclabuvir(BMS-791325), the EC50, IC50,and affinity,of Beclabuvir(BMS-791325), For the detailed information of Beclabuvir(BMS-791325), the solubility of Beclabuvir(BMS-791325) in water, the solubility of Beclabuvir(BMS-791325) in DMSO, the solubility of Beclabuvir(BMS-791325) in PBS buffer, the animal experiment (test) of Beclabuvir(BMS-791325), the cell expriment (test) of Beclabuvir(BMS-791325), the in vivo, in vitro and clinical trial test of Beclabuvir(BMS-791325), the EC50, IC50,and affinity,of Beclabuvir(BMS-791325), Please contact DC Chemicals.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC8612	Simeprevir(TMC-435)	Simeprevir (TMC 435350) is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).
DC8178	Beclabuvir(BMS-791325)	non-nucleoside inhibitor of the NS5B
DC11494	INX-08189	INX-08189 is a phosphoramidate prodrug of O-6-methyl-2-C-methyl guanosine, potent inhibitor of HCV NS5B polymerase with IC50 of 10 nM in replicon assay.
DC11081	Coblopasvir	Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection..
DC11731	Ruzasvir	A potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 0.003, 0.016, 0.067, 0.036, 0.007, and 0.007 nM for GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a, and Gt4a, respectively..
DC11825	MK-8876	A novel, broadly acting non-nucleoside inhibitor of HCV NS5B polymerase with IC50 of 3 nM and 2 nM for GT1b and GT2a, respectively.
DC11823	BMS-929075	A highly potent, selective, orally bioavailable HCV NS5B polymerase inhibitor with IC50 of 9, 4, and 18 nM for GT1a, GT1b, and GT1b-C316N mutant in HCV replicon assay, respectively.